Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Sep 9;17(1):723. doi: 10.1186/s12864-016-3042-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 4 — Validation of target kinases by inhibitors. a left panel: HCC-827 and CHP-212 cells were treated with indicated concentrations of CHEK1 inhibitor AZD7762 for 72 h. Then, cell viability was measured by Cell Titer Glo according to the manufacturer’s instructions. Middle panel: Fold changes for three independent sgRNAs for CHEK1 inhibitor AZD7762 are depicted at time point day 14. b Same as a) but CDK1,2,5,7,9 inhibitor and respective sgRNAs are shown. c Same as a) but AKT1/2/inhibitor MK2206 and respective sgRNAs are shown. d Same as a) but FGFR inhibitor BGJ398 and respective sgRNAs are shown. e Same as a) but BRAF inhibitor Vemurafenib and respective sgRNAs are shown